BIOMAT Database Logo BIOMAT Database Logo

Laboratory control of heparin and heparin fragment treatment: an experimental study. 1989

C Doutremepuich, and M C Lalanne, and M Guyot, and F Doutremepuich, and O De Sèze, and F Toulemonde
Laboratorie d'hématologie, Faculté de Pharmacie, Bordeaux, France.

UI MeSH Term Description Entries
D008297 Male Males
D010314 Partial Thromboplastin Time The time required for the appearance of FIBRIN strands following the mixing of PLASMA with phospholipid platelet substitute (e.g., crude cephalins, soybean phosphatides). It is a test of the intrinsic pathway (factors VIII, IX, XI, and XII) and the common pathway (fibrinogen, prothrombin, factors V and X) of BLOOD COAGULATION. It is used as a screening test and to monitor HEPARIN therapy. Activated Partial Thromboplastin Time,Cephalin-Kaolin Coagulation Time,Kaolin-Cephalin Coagulation Time,Thromboplastin Time, Partial,Coagulation Time, Cephalin-Kaolin,Cephalin Kaolin Coagulation Time,Coagulation Time, Cephalin Kaolin,Coagulation Time, Kaolin-Cephalin,Kaolin Cephalin Coagulation Time
D011516 Prothrombin A plasma protein that is the inactive precursor of thrombin. It is converted to thrombin by a prothrombin activator complex consisting of factor Xa, factor V, phospholipid, and calcium ions. Deficiency of prothrombin leads to hypoprothrombinemia. Coagulation Factor II,Factor II,Blood Coagulation Factor II,Differentiation Reversal Factor,Factor II, Coagulation,Factor, Differentiation Reversal,II, Coagulation Factor
D011919 Rats, Inbred Strains Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations or by parent x offspring matings carried out with certain restrictions. This also includes animals with a long history of closed colony breeding. August Rats,Inbred Rat Strains,Inbred Strain of Rat,Inbred Strain of Rats,Inbred Strains of Rats,Rat, Inbred Strain,August Rat,Inbred Rat Strain,Inbred Strain Rat,Inbred Strain Rats,Inbred Strains Rat,Inbred Strains Rats,Rat Inbred Strain,Rat Inbred Strains,Rat Strain, Inbred,Rat Strains, Inbred,Rat, August,Rat, Inbred Strains,Rats Inbred Strain,Rats Inbred Strains,Rats, August,Rats, Inbred Strain,Strain Rat, Inbred,Strain Rats, Inbred,Strain, Inbred Rat,Strains, Inbred Rat
D004353 Drug Evaluation, Preclinical Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. Drug Screening,Evaluation Studies, Drug, Pre-Clinical,Drug Evaluation Studies, Preclinical,Drug Evaluations, Preclinical,Evaluation Studies, Drug, Preclinical,Evaluation, Preclinical Drug,Evaluations, Preclinical Drug,Medicinal Plants Testing, Preclinical,Preclinical Drug Evaluation,Preclinical Drug Evaluations,Drug Screenings,Screening, Drug,Screenings, Drug
D005342 Fibrinolysis The natural enzymatic dissolution of FIBRIN. Fibrinolyses
D005343 Fibrinolytic Agents Fibrinolysin or agents that convert plasminogen to FIBRINOLYSIN. Antithrombic Drug,Antithrombotic Agent,Antithrombotic Agents,Fibrinolytic Agent,Fibrinolytic Drug,Thrombolytic Agent,Thrombolytic Agents,Thrombolytic Drug,Antithrombic Drugs,Fibrinolytic Drugs,Thrombolytic Drugs,Agent, Antithrombotic,Agent, Fibrinolytic,Agent, Thrombolytic,Agents, Antithrombotic,Drug, Antithrombic,Drug, Fibrinolytic,Drug, Thrombolytic,Drugs, Antithrombic
D006493 Heparin A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts. Heparinic Acid,alpha-Heparin,Heparin Sodium,Liquaemin,Sodium Heparin,Unfractionated Heparin,Heparin, Sodium,Heparin, Unfractionated,alpha Heparin
D006495 Heparin, Low-Molecular-Weight Heparin fractions with a molecular weight usually between 4000 and 6000 kD. These low-molecular-weight fractions are effective antithrombotic agents. Their administration reduces the risk of hemorrhage, they have a longer half-life, and their platelet interactions are reduced in comparison to unfractionated heparin. They also provide an effective prophylaxis against postoperative major pulmonary embolism. LMWH,Low-Molecular-Weight Heparin,Low Molecular Weight Heparin,Heparin, Low Molecular Weight
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

C Doutremepuich, and M C Lalanne, and M Guyot, and F Doutremepuich, and O De Sèze, and F Toulemonde
Laboratory control of heparin therapy.
September 1971, Journal of clinical pathology,
C Doutremepuich, and M C Lalanne, and M Guyot, and F Doutremepuich, and O De Sèze, and F Toulemonde
Heparin and uveitis. An experimental study.
December 1950, American journal of ophthalmology,
C Doutremepuich, and M C Lalanne, and M Guyot, and F Doutremepuich, and O De Sèze, and F Toulemonde
Heparin therapy and its laboratory control.
May 1970, British journal of haematology,
C Doutremepuich, and M C Lalanne, and M Guyot, and F Doutremepuich, and O De Sèze, and F Toulemonde
The laboratory control of heparin therapy.
May 1971, The Medical journal of Australia,
C Doutremepuich, and M C Lalanne, and M Guyot, and F Doutremepuich, and O De Sèze, and F Toulemonde
The laboratory control of heparin therapy.
July 1975, Current therapeutic research, clinical and experimental,
C Doutremepuich, and M C Lalanne, and M Guyot, and F Doutremepuich, and O De Sèze, and F Toulemonde
Current problems of the clinical use and laboratory control of heparin treatment.
January 1985, Therapia Hungarica (English edition),
C Doutremepuich, and M C Lalanne, and M Guyot, and F Doutremepuich, and O De Sèze, and F Toulemonde
[Heparin treatment of crotilid bites. Experimental and clinical study].
January 1976, Anesthesie, analgesie, reanimation,
C Doutremepuich, and M C Lalanne, and M Guyot, and F Doutremepuich, and O De Sèze, and F Toulemonde
The laboratory control of intravenous heparin therapy.
November 1971, The Medical journal of Australia,
C Doutremepuich, and M C Lalanne, and M Guyot, and F Doutremepuich, and O De Sèze, and F Toulemonde
Laboratory monitoring of unfractionated heparin treatment.
March 1995, Clinics in laboratory medicine,
C Doutremepuich, and M C Lalanne, and M Guyot, and F Doutremepuich, and O De Sèze, and F Toulemonde
The tPA-like activity induced by heparin and a heparin fragment binds on experimental thrombus.
April 1988, Thrombosis research,
Copied contents to your clipboard!